InMed Pharmaceuticals

InMed Pharmaceuticals

InMed is a biopharmaceutical company that specializes in the discovery and development of novel, cannabinoid-based therapeutics for the treatment of diseases with high unmet medical need.
Grow Rooms & Boxes
Extraction Equipment
1d 5d 1m 6m 1y Max

About InMed Pharmaceuticals

InMed employs a highly scientific approach to designing and developing medicines, which will help unlock the full potential of cannabinoid pharmaceuticals. One proprietary technology is our bioinformatics platform, which uses a computer-based drug candidate selection process to reach high-probability conclusions from massive, publicly available databases together with an internal library of cannabinoid drug information.

InMed is also developing a robust, high-yield, microbial-based biosynthesis process designed to enable the manufacturing of the multitude of cannabinoids (90+) found from natural sources. InMed products are designed to be bio-identical to the naturally-occurring cannabinoids and the process envisioned to offer cost and time savings, and superior ease, control and quality of manufacturing when compared to alternative methods.

Team

Eric A. Adams,
Chief Executive Officer & President
Sazzad Hossain
Chief Scientific Officer
Jeff Charpentier
Chief Financial Officer
Josh Blacher
Chief Business Officer
Alexandra D.J. Manci...
Senior Vice President, Clinical & Regulatory Affai...
Eric C. Hsu
Vice President, Pre-Clinical Research & Developmen...
Michael Woudenberg
Vice President, Chemistry, Manufacturing & Control...
William Garner,
Chairman of the Board of Director
Martin Bott
Director
Adam Cutler
Director
Andrew Hull
Director

Participation in events

$ 1.39
6.11%
Open:
1.35
High:
1.47
Low:
1.33
Symbol:
IN